老年人与中青年晚期非小细胞肺癌化疗后的生存分析比较  

Compared survival analysis between elder and younger patients with late stage of non-small cell lung cancer on chemotherapy

作　　者：刘天舒[1] 庄荣源[1] 陈勇[1] 金文[1] 崔越宏[1] 宋燕[1] 

机构地区：[1]复旦大学附属中山医院化疗科,上海200032

出　　处：《临床肿瘤学杂志》2006年第9期687-689,共3页Chinese Clinical Oncology

摘　　要：目的：比较老年人和中青年人晚期非小细胞肺癌的化疗及生存情况。方法：回顾性分析2001年～2003年我院肿瘤中心收治的Ⅲ～Ⅳ期非小细胞肺癌患者162例，其中年龄大于65岁的老年组有97例，年龄小于或等于65岁的中青年组有65例，比较两组的疗效及生存率。结果：老年组和中青年组接受化疗周期的中位数分别为3次和4次。没有患者达到完全缓解，治疗有效率两组分别为28．9％和32．3％（P〉0．05），Ⅲ度和Ⅳ度骨髓抑制的发生率两组分别为12．4％和7．7％（P〉0．05）。中位生存时间（MST）两组分别为13个月和11个月（P〉0．05）。Cox回归分析发现肿瘤分期和行为状态评分为影响预后的因素。结论：老年非小细胞肺癌患者接受化疗的安全性和疗效与年轻人相比无明显差异。Objective：To compare the survival rates of elder and younger patients in advanced stage of non-small cell lung cancer （NSCLC） who had received chemotherapy. Methods ：162 NSCLC patients with stage Ⅲ-Ⅳ who had received chemotherapy in the tumor center of our hospital from Jan 2001 to Jun 2003 were retrospectively analyzed. Among them, 97 cases with their age over 65 years old were in the elder group, while 65 cases with the age younger than 65 were in the younger group. Treatment efficacy and survival rate were compared in the two groups. Results： The median cycles of chemotherapy received were 3 and 4 in the elder and younger group respectively, no complete remission （CR） occurred in the two groups. Response rates were 28.9% and 32.3% （ P 〉 0.05 ） , occurrence rates of Ⅲ/Ⅳ myelosuppression were 12.4% and 7.7% （P 〉 0.05 ）. Median survival time（MST） in the two groups were 13 and 11 months （ P 〉 0.05 ）. Cox regression analysis showed tumor stage and performance status were the factors influenced the prognosis. Conclusion：There is the same safety and efficacy between elder NSCLC patiewts and younger NSCLC patients by receiving chemotherapy.

关 键 词：老年人 中青年人 非小细胞肺癌 化疗 生存分析 

分 类 号：R734.2[医药卫生—肿瘤]